Combination product for use in tumor vaccination

3-6. (canceled)

8-10. (canceled)

(canceled)

15-17. (canceled)

(canceled)

A non-tumor antigen, or a nucleic acid sequence encoding said non-tumor antigen, for use in eliciting or directing an immune response against a tumor in a subject;

• wherein said non-tumor antigen or said nucleic acid is prepared for intratumoral delivery;
• and wherein said subject is vaccinated with an immunogenic composition comprising said non-tumor antigen as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.

(canceled)

A cell having a dendritic phenotype comprising a non-tumor antigen, or a nucleic acid sequence encoding said non-tumor antigen, for use in marking a tumor as a target for an immune response in a subject, wherein said cell having a dendritic phenotype is for intratumoral administration.

A fusion protein or a protein-protein conjugate comprising a first protein linked to a second protein, wherein said first protein comprises a diphtheria toxin or a receptor-binding domain of diphtheria toxin, and said second protein comprises a non-tumor antigen polypeptide.

A method for eliciting an immune response against a subject suffering from a tumor, comprising the steps of:

• administering to a subject suffering from a tumor a pharmaceutically effective amount of a non-tumor antigen polypeptide, or a nucleic acid encoding said polypeptide, prepared for intratumoral delivery;
• and
• administering to said subject a pharmaceutically effective amount of an immunogenic composition comprising said polypeptide as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.

31-32. (canceled)